An open study of sertraline in patients with major depression who failed to respond to moclobemide

References

• Thase M E, Rush A J. When at first you don't succeed: sequential strategies for antidepressant nonresponders. Journal of Clinical Psychiatry 1997; 58: 23–29, (Suppl. 13)
   PubMed Web of Science ®Google Scholar
• Dinan T. Treatment approaches to therapy-resistant depression. Journal of Psychopharmacology 1995; 9: 199–204, (Suppl.)
   PubMed Web of Science ®Google Scholar
• Andrews J M, Nemeroff C B. Contemporary management of depression. American Journal of Medicine 1994; 97: 24–32, (Suppl. 6A)
   Web of Science ®Google Scholar
• Shelton R C. The role of sertraline in the management of depression. Clinical Therapeutics 1994; 16: 768–782
   PubMed Web of Science ®Google Scholar
• Fabre L F, Abuzzahab F S, Amin M, et al. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biology of Psychiatry 1995; 38: 592–602
   PubMed Web of Science ®Google Scholar
• Feiger A, Kiev A, Shrivastava R K, Wisselink P G, Wilcox C S. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. Journal of Clinical Psychiatry 1996; 57: 53–62, (Suppl. 2)
   PubMed Web of Science ®Google Scholar
• Lydiard R B, Stahl S M, Hertzman M, Harrison W M. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. Journal of Clinical Psychiatry 1997; 58: 484–491
   PubMed Web of Science ®Google Scholar
• Ekselius L, von Knorring L, Eberhard G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. International Clinical Psychopharmacology 1997; 12: 323–331
   PubMed Web of Science ®Google Scholar
• Preskorn S H, Lane R M. Sertraline 50 mg daily: the optimal dose in the treatment of depression. International Clinical Psychopharmacology 1995; 10: 129–141
   PubMed Web of Science ®Google Scholar
• Fulton B, Benfield P. Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs 1996; 52: 450–474
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. Journal of Neurology Neurosurgery and Psychiatry 1960; 23: 56–62
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology. National Institute of Mental Health, Rockville, MD 1976, US Department of Health, Education and Welfare publication (ADM) 76–338
   Google Scholar
• Montgomery S A, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979; 134: 382–389
   PubMed Web of Science ®Google Scholar
• Beck A T, Ward C H, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961; 4: 561–571
   PubMed Web of Science ®Google Scholar
• Orsel Donbak S, Turkcapar M H, Ozturk Kilic E Z, et al. Moclobemide and sertraline in the treatment of depressive disorders: a comparative study. Acta Psychiatrica Belgica 1995; 95: 139–151
   PubMedGoogle Scholar
• Brown W A, Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another?. Journal of Clinical Psychiatry 1995; 56: 30–34
   PubMed Web of Science ®Google Scholar
• Zarate C A, Kando J C, Tohen M, Weiss M K, Cole J O. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline?. Journal of Clinical Psychiatry 1996; 57: 67–71
   PubMed Web of Science ®Google Scholar
• Thase M E, Blomgren S L, Birkett M A, Apter J T, Tepner R G. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. Journal of Clinical Psychiatry 1997; 58: 16–21
   PubMed Web of Science ®Google Scholar
• Filip V, Selfertova D, Ceskova E, Svestka J, Korinkova V, Klaschka J. Open non-comparative multicenter pilot study on the efficacy and tolerance of sertraline in the treatment of patients with major depression who cannot tolerate tricyclic antidepressants. Behavioural Pharmacology 1995; 6: 31, (Suppl. 1)
   Web of Science ®Google Scholar
• Thase M E, Keller M B, Gelenberg A S, Gelenberg A J, Hirschfeld R MA, Scatzberg A. Double-blind crossover antidepressant study: sertraline versus imipramine. Psychopharmacology Bulletin 1995; 31: 535
   Google Scholar